DMD # 35907

Introduction
Fingolimod (FTY720, Gilenya™) is a new chemical entity recently approved in the US as a therapy for relapsing multiple sclerosis (Kappos et al., 2006; Brown et al., 2007) . The compound is metabolically phosphorylated to form (S)-configured fingolimod phosphate. The latter is a potent agonist at different sphingosine 1-phosphate receptors, including those of type 1, while the (R)-enantiomer, which was not observed as a metabolite, and fingolimod itself show low or negligible activity at these receptors (Hale et al., 2004; Albert et al., 2005) . Activation of type 1 sphingosine 1-phosphate receptors on lymphocytes by (S)-fingolimod phosphate results in a suppression of the egress of lymphocytes from lymph nodes and a prevention of their recirculation to other organs, including the central nervous system (Brinkmann, 2007; Chiba, 2005) . Hence, fingolimod exhibits a novel mechanism of action. The compound does not impair T-or B-lymphocyte activation, proliferation, or effector functions at clinically relevant concentrations (Pinschewer et al., 2000) . Fingolimod may also have direct effects in the central nervous system because sphingosine 1-phosphate receptors are present in this tissue (Bryan et al., 2008 ) and (S)-fingolimod phosphate can be assumed to be present as well, based on results in the rat (Foster et al., 2007; Novartis, unpublished data) .
The pharmacokinetics of fingolimod and fingolimod phosphate in man have been described previously (Kovarik et al., 2007a,b) . Two metabolites of fingolimod other than its phosphate have been quantified in clinical studies (e.g. Kovarik et al., 2005; Kovarik et al., 2006; Kovarik et al., 2007b ). However, a full description of the biotransformation of the compound has not been published. In this communication we present the results of an absorption, distribution, metabolism, and excretion study in healthy male volunteers following a single oral dose of in vitro and the involved enzymes are presented in an accompanying publication (Jin et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. and 5 weeks after dosing, except for medication required to treat adverse events. The subjects had to fast for at least 10 h prior to dosing and to continue fasting for at least 4 h thereafter.
Each subject received a single oral dose of 5 mg [ 14 C]fingolimod hydrochloride (4.5 mg referring to free base), formulated as a drinking solution. The radioactivity dose was 2.16 MBq.
The whole body radiation dose was below 1.0 mSv.
Blood was collected at predose, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 312, 480 , and 816 h postdose into EDTA-containing vacuum tubes by direct venipuncture or by an indwelling cannula inserted in a forearm vein. Up to 72 h, blood volumes of 23 ml were taken. At later times, the sampling volume was reduced to 5 ml. After aliquoting for the different assays, the blood samples were frozen and stored at approximately -80°C until analysis.
All urine was collected in time-fractions of 0-6 h, 6-12 h, 12-24 h, and thereafter in 24-h fractions up to 240 h. In addition, all urine was collected during Day 13 (288-312 h), Day 20
(456-480 h), and Day 34 (792-816 h). During the collection periods, the urine was kept refrigerated at 4-8°C. All feces were collected after dose administration up to 240 h postdose.
Urine and feces samples were stored at ≤ -20°C until analysis.
Aliquots of blood, urine, and feces were assayed for radioactivity by liquid scintillation counting. These analyses were performed by RCC Ltd. (Itingen, Switzerland). Blood concentrations of fingolimod were determined by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay at Novartis. Metabolite profiles in blood, urine, and feces were obtained by high-performance liquid chromatography (HPLC) with radioactivity detection, and metabolite structures were characterized by mass spectrometry, wet-chemical methods, and comparison with reference compounds at Novartis. Details are given below.
This article has not been copyedited and formatted. The final version may differ from this version. Plus (Packard). The measurements were performed on a Packard Tri-Carb 2500 TR liquid scintillation counter or a Packard 2550 TR/LL low-level counter with counting times of 10-30 min for blood, 10 min for urine, and 10 min for feces. The long counting times of 30 min were used to improve the counting statistics in case of blood samples containing low levels of radioactivity (20-100 dpm/ml). Quench correction was performed by an external standard method.
Determination of Fingolimod Concentrations in Blood.
Fingolimod in blood was quantified by LC-MS/MS after liquid-liquid extraction. Aliquots of 0.5 ml were spiked with 100 µl of internal standard solution, containing 4 ng of (1,1,3,3-2 H 4 )fingolimod, alkalinized with 0.5 ml of 100 mM aqueous NaOH, and extracted with 5 ml of a 75:25 (v/v) mixture of tert-butyl methyl ether and dichloromethane. The samples were shaken for 30 min and centrifuged. The organic layer was removed, evaporated to dryness, and re-constituted in 200 µl of a 1:1 (v/v) mixture of 20 mM aqueous ammonium acetate and methanol. A 100 µl aliquot of the final extract was injected onto a 4.6 x 50 mm Symmetry Shield RP8 column from Waters (3.5 µm particles;
Milford, MA, USA), protected by a 3.9 x 20 mm pre-column of the same stationary phase. The components were eluted with a gradient of 20 mM aqueous ammonium acetate versus methanol This article has not been copyedited and formatted. The final version may differ from this version. to m/z 259 were monitored, respectively. The lower limit of quantitation was 0.26 pmol/ml (0.080 ng/ml). The stability of fingolimod and (S)-fingolimod phosphate during the blood and feces preparation and HPLC analysis was investigated using blank blood and feces spiked with and the nonpolar metabolites M27 to M30 were investigated by wet-chemical methods.
Determination of Metabolite Profiles in
Briefly, the polar metabolites were isolated from blood, urine, and feces by HPLC using similar sample preparation procedures and the same HPLC method as described above for the Product ion spectra of the [M+H] + ions of the isolated components were obtained by nano-LC-MS/MS analysis on the same instrument, using a Waters 150 mm x 75 µm Symmetry C18 column (3.5 µm particle size) and the same mobile phases as for LC-MS.
To check whether metabolite M22 might be an acyl glucuronide, its stability in alkaline solution was investigated. For this purpose, the metabolite was isolated from urine by HPLC and incubated for 2 h at room temperature in a 1:2 (v/v) mixture of methanol and 0.4 M aqueous ammonium acetate buffer of pH 10, followed by HPLC analysis.
For obtaining further structural information on the nonpolar metabolites M27 to M30 and additional nonpolar trace components, these metabolites were subjected to alkaline hydrolysis, followed by analysis of the products. To this end, the nonpolar metabolites were isolated from a representative blood sample (36 h blood pool across all four subjects) all together in one HPLC fraction. The pool of nonpolar metabolites was subjected to hydrolysis in a 4:1 (v/v) mixture of ethanol and 2.5 M aqueous KOH for 2 h at 90°C, followed by neutralization and HPLC analysis.
Pharmacokinetic Evaluations. Pharmacokinetic parameters were calculated from blood concentration-time data using non-compartmental methods. Areas under the concentration-time curve (AUC values) were determined by the linear trapezoidal method and extrapolated to infinity using the equation AUC t-∞ = C t · t 1/2 / ln 2, where C t is the last observed concentration above the lower limit of quantitation (fingolimod) or limit of detection (metabolites). subject experienced severe sinus bradycardia, starting at 4 h postdose, associated with temporary hypotension and syncope, while no abnormalities were observed in the twelve-lead ECG evaluation other than sinus bradycardia. After treatment with atropine (twice 0.5 mg), the subject's heart rate recovered to baseline conditions at approximately 24 h postdose. Another subject experienced moderate fatigue of 8.5 h duration during the first day after the administration of fingolimod. No concomitant medication was administered in this case. The safety laboratory parameters showed no clinically significant abnormalities or changes in any of the four subjects that would suggest a relationship to the study drug.
Blood Concentrations of Radioactivity, Fingolimod, and Fingolimod Phosphate. The blood concentrations of total radiolabeled components (radioactivity) and fingolimod increased slowly after dosing, reaching a first maximum around 12 h, followed by a shallow dip and a second maximum at 36 h. Thereafter, the concentrations decreased with estimated terminal halflives of 382 h (15.9 days) and 137 h (5.7 days) for radioactivity and fingolimod, respectively. The blood concentrations of fingolimod phosphate, derived from the metabolite profiles, reached their maximum at 12 h and decreased thereafter with a terminal half-life of about 166 h (6.9 days), hence approximately in parallel to fingolimod (Tables 1 and 2 ; Fig. 2 ). About 15% of the AUC 0-∞ of radioactivity accounted for fingolimod, 8% for fingolimod phosphate while the rest was due to metabolites other than fingolimod phosphate (see below).
This article has not been copyedited and formatted. The final version may differ from this version. Examples of mass spectra are shown in Fig. 4 A to C; structures of the metabolites are given in In contrast to fingolimod, its phosphate has an asymmetric center and can, therefore, exist as one of two enantiomers or a mixture of the two. As described previously (Albert et al., 2005) , only the (S)-enantiomer was detected in human blood, both at early (12 h) and later times after dosing (72 h). The (R)-enantiomer was not detected (limit of detection: 3% of total fingolimod phosphate).
Metabolite Profiles in Blood, Urine, and Feces. Fingolimod-related components in blood covered a wide range of polarities and had, therefore, to be analyzed in two fractions: a polar fraction containing the major part and a nonpolar fraction containing a minor part of the total radioactivity. Some compounds were observed in both fractions. Attempts to analyze the two fractions in a single HPLC run resulted in poor chromatographic peak-shapes and were not pursued. Because of limitations in sample size, blood had to be pooled across subjects for some of the analyses. The recovery of radioactivity after sample preparation was 87-98% for blood sampled between 12 h and 480 h (sum of polar and nonpolar fractions) but dropped to 63% at 816 h postdose. All radioactivity injected onto the HPLC column was recovered in the column This article has not been copyedited and formatted. The final version may differ from this version. and nonpolar trace components of unknown structure, eluting mainly between 0 and 7 min and between 60 and 85 min, respectively, were observed as well. Quantitative data are given in Table 2 , and examples of radiochromatograms are shown in Fig. 3 Metabolite profiles in the 0-240 h urine and feces pools were analyzed for each of the four subjects individually. The recovery of radioactivity after sample preparation was 100% in case of urine and 63% in case of feces. The recovery of radioactivity in the HPLC effluent, relative to the amount injected, was 100% for urine and 94% for feces. Quantitative data on the fingolimodrelated components in urine and feces are given in Table 3 (Table 4 ). About one third of the administered radioactivity appeared in urine and feces within the first three days after administration. After 10 days, on average 62% of the dose was recovered in the excreta: 52% in urine and 10% in feces. Small amounts of radioactivity in the additional urine fractions, collected after 240 h, indicated that the excretion of radioactivity was still continuing. The excretion rate of radioactivity in urine between 96 h and 816 h and in feces between 96 h and 240 h decreased close to mono-exponentially with apparent half-lives of about 173 h (7.2 days) in urine and about 65 h (2.7 days) in feces (Fig. 6 ). Based on these values, the urinary and fecal excretion of radioactivity between time zero and infinity was estimated at 81% and 11% of dose, respectively.
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Discussion
Fingolimod was absorbed slowly after oral administration. The blood concentrations showed maxima at 12 h and 36 h with a small dip in between, followed by a slow decrease (Fig. 2 ).
Similar time profiles had been found previously (Budde et al., 2002; Kovarik et al., 2004) . The extent of absorption was estimated ≥ 84% of dose, based on the amount of radioactivity excreted in urine (81% of dose; Table 4 ) and the amount of metabolites excreted in feces (≥ 3% of dose; Table 3 ). The absolute bioavailability (F) could not be determined in the present study but can be assumed to be high (Kovarik et al., 2007a) . The low apparent clearance of fingolimod (CL/F, 8.7 ± 3.7 l/h), its high apparent terminal volume of distribution (V z /F, 1509 ± 225 l), and its long terminal half-life (137 ± 55 h; Table 1 ) are in line with data from previous studies (Kovarik et al., 2004; Kovarik et al., 2006) . Fingolimod phosphate has been demonstrated to be the active principle (Brinkmann et al., 2002; Mandala et al., 2002) while fingolimod itself showed negligible pharmacological activity.
Of the two enantiomers of fingolimod phosphate, the (S)-form is pharmacologically active while the (R)-form shows only marginal activity as an agonist at sphingosine 1-phosphate receptors or as an inhibitor of lymphocyte migration (Hale et al., 2004; Albert et al., 2005; Kiuchi et al., 2005) . Only the (S)-enantiomer of fingolimod phosphate was observed in blood (Albert et al., 2005 Jin et al., 2010) . Hence, the phosphorylation of fingolimod is reversible, in line with the approximately constant concentration ratio of fingolimod to fingolimod phosphate in blood during the elimination phase (Fig. 2, inset) , observed also in a previous study (Kovarik et al., 2007b) . The phosphorylation of fingolimod is catalyzed predominantly by sphingosine kinase type 2 with a smaller contribution by sphingosine kinase type 1 (Billich et al., 2003; Paugh et al., 2003) . The dephosphorylation of fingolimod phosphate seems to be catalyzed mainly by the lipid phosphate phosphohydrolases LPP1a and LPP3 and to a smaller extent by the specific sphingosine 1-phosphate phosphatase SPP1 (Yamanaka et al., 2008; Mechtcheriakova et al., 2007) .
The oxidative biotransformation of fingolimod occurred predominantly or exclusively by hydroxylation at the methyl terminal of the octyl chain. The resulting primary metabolite M12
was not observed in vivo due to rapid further oxidation to the carboxylic acid metabolite M1.
However, in incubates with human liver microsomes, M12 was the major metabolite of fingolimod, formed predominantly by CYP4F2 and possibly other enzymes of the CYP4F subfamily with only minor contributions by other cytochrome P450 enzymes (Jin et al., 2010) .
Metabolite M1 underwent further biotransformation by sequential losses of two-carbon units, forming the carboxylic acid metabolites M2, M3, and M4 through Among the nonpolar metabolites in blood, the two major ones (M29 and M30) and two minor ones (M27 and M28) were characterized as ceramide analogs of fingolimod, possibly formed by the action of (dihydro)ceramide synthase and potentially also by ceramidase (reverse reaction), in analogy to the biosynthesis of endogenous dihydroceramide and ceramide (Merrill, 2002) . The formation of the ceramide analogs of fingolimod might be reversible due to the action of ceramidase. However, this was not investigated.
These biotransformation pathways of fingolimod are all quite unusual for a xenobiotic and The major fingolimod-related components in the systemic circulation, as judged from their AUC values (Table 2) , were fingolimod itself, fingolimod phosphate, M3, M29, and M30. M2, M27, and M28 were present in traces only. In terms of maximum concentration (C max ), fingolimod, fingolimod phosphate, and M3 were the major circulating components. M29 and The elimination of fingolimod occurred almost exclusively by metabolism, as opposed to direct excretion. No fingolimod was excreted in urine and only 2-3% of the dose appeared in the feces (0-240 h) in the form of unchanged compound. Among the primary biotransformation pathways (phosphorylation, hydroxylation to M12, and formation of ceramide analogs), the hydroxylation was clearly the major contributor to the elimination of fingolimod. Elimination due to phosphorylation was a minor process because only 1-2% of dose was recovered in the feces in the form of fingolimod phosphate, and no fingolimod phosphate was found in urine. Reversible phosphorylation of fingolimod is not an elimination pathway but rather a distribution-type process. The formation of the ceramide analogs does not seem to be a major elimination pathway of fingolimod either, because no ceramide analogs were detected in urine or feces. However, excretion of a minor amount of ceramide analogs in the feces cannot be excluded as these nonpolar components might not have been recovered efficiently from the fecal matrix. The elimination of fingolimod phosphate occurred predominantly by dephosphorylation back to fingolimod, followed by oxidation of the latter. Direct oxidation of fingolimod phosphate does not seem to occur, as mentioned above, and direct excretion (1-2% of dose detected in feces 0-240 h, no fingolimod phosphate detected in urine) appeared to be a minor process.
The excretion of radioactivity was slow and still incomplete after 10 days of sample collection (approximately 52% and 10% of dose in urine and feces, respectively). However, by extrapolation an estimate of total excretion up to infinity of 92% of dose was obtained (Table 4) (Table 3 ).
In conclusion, orally administered fingolimod is absorbed slowly but almost completely, This article has not been copyedited and formatted. The final version may differ from this version. Table 3 Amounts Material lost during sample preparation -3.7 ± 0.8 3.7 ± 0.8
Material lost during chromatography -0.4 ± 0.1 0.4 ± 0.1 Total radioactivity 52.3 ± 6.3 9.9 ± 1.7 62.1 ± 7.6 -: not detected.
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Data from healthy male subjects treated with a single oral dose of 4.5 mg [ 
